hcv
two
envelop
protein
name
play
import
role
cell
entri
two
main
pathway
direct
fusion
plasma
membran
receptormedi
endocytosi
fusion
hcv
envelop
protein
trigger
low
ph
within
endosom
lysosomotrop
agent
la
chloroquin
ammonium
chlorid
nh
cl
weak
base
penetr
lysosom
proton
form
increas
intracellular
ph
investig
antivir
effect
la
chloroquin
nh
cl
ph
depend
endocytosi
hcv
pseudoparticl
hcvpp
genotyp
produc
use
infect
liver
cell
toxicolog
effect
chloroquin
nh
cl
test
liver
cell
mtt
cell
prolifer
assay
antivir
screen
chloroquin
nh
cl
liver
cell
infect
hcvpp
genotyp
presenc
absenc
differ
concentr
chloroquin
luciferas
activ
determin
use
luminomet
result
demonstr
chloroquin
nh
cl
show
reduct
viru
infect
mm
concentr
respect
result
suggest
inhibit
hcv
fusion
step
increas
lysosom
ph
better
option
treat
chronic
hcv
hepat
c
viru
hcv
envelop
posit
strand
rna
viru
classifi
famili
flavivirida
hcv
caus
acut
chronic
hepat
infect
eventu
lead
perman
liver
damag
hepatocellular
carcinoma
death
estim
three
four
million
peopl
infect
hcv
everi
year
hcv
genom
encod
singl
polyprotein
precursor
amino
acid
polyprotein
precursor
coand
posttransl
process
cellular
signal
peptidas
signal
peptid
peptidas
viral
proteas
yield
four
structur
core
six
non
structur
protein
hcv
envelop
form
glycoprotein
heterodim
essenti
viru
entri
cell
hcv
fusion
enhanc
low
ph
suggest
hcv
enter
cell
via
endosom
pathway
andor
undergo
conform
modif
allow
fusion
viral
cellular
membran
six
major
subtyp
hcv
classif
base
nucleotid
variat
among
differ
hcv
isol
occur
differ
proport
differ
part
world
genotyp
common
genotyp
unit
state
europ
preval
hcv
genotyp
pakistan
follow
present
vaccin
avail
prevent
hcv
infect
due
high
degre
strain
variat
current
therapeut
option
hepat
c
limit
especi
genotyp
genotyp
pegyl
interferon
combin
ribavirin
lead
sustain
virolog
respons
patient
howev
therapi
expens
often
associ
side
effect
may
lead
discontinu
therapi
hemolyt
anemia
cough
short
breath
treatogen
common
advers
effect
associ
ribavirin
treatment
muscl
ach
fatigu
neuropsychiatr
advers
effect
lead
prematur
cessat
therapi
patient
moreov
cost
interferon
month
treatment
rang
pkr
beyond
financi
rang
patient
henc
need
develop
anti
hcv
agent
less
toxic
efficaci
costeffect
term
lysosomotrop
agent
introduc
deduv
cowork
design
substanc
taken
select
lysosom
definit
leav
open
chemic
natur
lysosomotrop
substanc
mechan
uptak
lysosomotrp
agent
nh
chloroquin
methylamin
penetr
acid
compart
cell
accumul
proton
form
result
increas
intravesicular
ph
chloroquin
wide
use
treatment
malaria
wellestablish
inhibitor
autophag
proteolysi
act
inhibit
acidif
lysosom
endosom
report
lysosomotrop
agent
chloroquin
nh
cl
exert
direct
antivir
effect
sever
rna
virus
includ
coronavirus
flavivirus
human
immunodefici
viru
hiv
moreov
clinic
studi
demonstr
safeti
toler
efficaci
lysosomotrop
agent
antivir
treatment
hiv
infect
current
studi
hcv
entri
block
lysosomotrop
agent
firstli
toxicolog
analysi
chloroquin
nh
cl
done
liver
cell
toxicolog
analysi
antivir
effect
studi
hcvpp
genotyp
hek
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
iuml
penicillin
ml
streptomycin
atmospher
co
kindli
provid
dr
zafar
nawaz
biochemistri
molecular
biolog
depart
univers
miami
usa
express
vector
encod
glycoprotein
hcv
genotyp
gener
insert
nonpackag
cmv
promoterdriven
express
construct
cmvgagpol
murin
leukemia
viru
mlv
packag
construct
encod
mlv
gag
pol
gene
ptgluciferas
plasmid
provid
dr
jaean
dubison
franc
hcvpp
produc
cotransfect
cell
equal
amount
three
express
vector
describ
previous
supernat
contain
hcvpp
harvest
h
later
filter
pores
membran
store
use
infect
cell
mtt
bromid
rapid
sensit
invitro
procedur
evalu
cellular
toxic
compound
mtt
substanc
reduc
mitochondri
succin
dehydrogenas
live
cell
purpl
formazan
crystal
solubl
aqueou
water
absorpt
dissolv
formazan
visibl
region
correl
number
viabl
cell
investig
cellular
toxic
cell
plate
plate
h
differ
concentr
chloroquin
nh
cl
ad
plate
seal
kept
atmospher
co
h
h
fresh
media
mtt
solut
mgml
pb
ad
well
column
wrap
plate
aluminium
foil
incub
h
media
care
remov
ad
dmso
dissolv
formazan
crystal
column
mtt
formazan
product
determin
measur
absorb
enzymelink
immunosorb
assay
elisa
plate
reader
test
wavelength
nm
refer
wavelength
nm
cell
viabil
obtain
use
follow
equat
percent
cell
viabil
test
nm
nmcontrol
nm
nm
investig
antifus
effect
chloroquin
nh
cl
cell
incub
presenc
absenc
chloroquin
nh
cl
min
min
cell
infect
hcvpp
genotyp
presenc
absenc
differ
concentr
chloroquin
nh
cl
incub
addit
h
h
cell
lyse
luciferas
activ
determin
use
luminomet
statist
analysi
done
use
spss
softwar
version
spss
inc
data
present
mean
sd
numer
data
analyz
use
student
ttest
anova
p
valu
consid
statist
signific
mtt
assay
wide
use
test
evalu
cytotox
compoundsherb
cell
cultur
mtt
substanc
reduc
mitochondri
succin
dehydrogenas
live
cell
purpl
formazan
crystal
solubl
aqueou
water
absorpt
dissolv
formazan
visibl
region
correl
number
aliv
cell
cytotox
effect
chloroquin
nh
cl
analyz
h
incub
cell
differ
concentr
compound
figur
show
cell
prolifer
liver
cell
unaffect
high
concentr
toxicolog
analysi
mtt
prolifer
assay
antivir
activ
chloroquin
nh
cl
test
non
toxic
concentr
envelop
virus
enter
cell
two
main
pathway
direct
fusion
plasma
membran
receptormedi
endocytosi
fusion
viral
envelop
protein
trigger
low
ph
within
endosom
lysosomotrop
agent
chloroquin
nh
cl
use
demonstr
ph
sensit
viru
entri
therefor
test
infect
hcvpp
treatment
target
cell
differ
concentr
chloroquin
nh
cl
hcvpp
genotyp
demonstr
dosedepend
inhibit
presenc
chloroquin
nh
cl
chloroquin
nh
cl
show
greater
reduct
viru
infect
mm
concentr
respect
suggest
phsensit
rout
viru
entri
figur
hcv
entri
multistep
process
requir
four
cellular
receptor
fusion
endocytosi
hcv
fusion
depend
viral
dose
occur
within
specif
ph
rang
target
ph
depend
endocytosi
use
tool
identifi
antivir
drug
major
advanc
look
hcv
entri
process
develop
hcvpp
consist
nativ
hcv
envelop
glycoprotein
assembl
onto
system
potenti
power
tool
identifi
character
molecul
block
hcv
entri
studi
hcvpp
local
hcv
genotyp
produc
studi
earli
entri
step
mediat
hcv
envelop
glycoprotein
assay
base
quantif
retrovir
dna
synthesi
occur
soon
fusion
retrovir
particl
cellular
membran
presum
assay
depend
entri
step
mediat
heterodim
bind
endocytosi
fusion
activ
revers
transcriptas
hcvpp
retrovir
core
intracellular
subcompart
lysosom
endosom
acid
natur
ph
lysosomotrop
agent
chloroquin
nh
cl
weak
base
tendenc
accumul
compart
lysosomotrop
agent
captur
proton
insid
lysosom
accumul
figur
ratio
intraextra
lysosom
concentr
substanc
equal
ratio
concentr
hydrogen
ion
lysosom
vicin
ie
suppos
ph
lysosom
cytoplasm
amount
permeabl
form
lysosomotrop
agent
pass
membran
depend
substanc
pka
valu
ph
valu
solut
higher
pka
valu
lower
permeabl
form
ratio
led
assumpt
specif
uptak
lysosomotrop
substanc
lysosom
depend
acid
ph
compart
iontrap
weak
base
model
suitabl
weak
base
pka
around
nh
cl
chloroquin
lysosom
weak
base
known
affect
acid
vesicl
lead
dysfunct
sever
protein
previou
studi
chloroquin
cl
demonstr
multipl
effect
mammalian
cell
addit
elev
endosom
ph
includ
prevent
termin
glycosyl
immunoglobulin
ad
virusinfect
cell
chloroquin
inhibit
later
stage
vesicular
stomat
viru
matur
inhibit
glycoprotein
express
cell
surfac
inhibit
product
infecti
particl
interf
termin
glycosyl
glycoprotein
increas
ph
chloroquin
nh
cl
firstli
inhibit
low
ph
confirm
chang
trigger
fusion
penetr
uncoat
secondli
inhibit
posttransl
modif
hcv
envelop
protein
figur
result
demonstr
chloroquin
nh
cl
inhibit
hcvpp
entri
dosedepend
manner
non
toxic
concentr
chloroquin
nh
cl
result
greater
reduct
viru
infect
concentr
mm
respect
suggest
phsensit
rout
viru
entri
figur
conclus
inhibit
hcv
entri
increas
ph
lysosomotrop
agent
import
target
identifi
new
drug
hcv
combin
lysosomotrop
agent
interferon
better
option
treat
chronic
hcv
